Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival
- 2k Downloads
To establish the potential for tumour heterogeneity in non-small cell lung cancer (NSCLC) as assessed by CT texture analysis (CTTA) to provide an independent marker of survival for patients with NSCLC.
Materials and methods
Tumour heterogeneity was assessed by CTTA of unenhanced images of primary pulmonary lesions from 54 patients undergoing 18F-fluorodeoxyglucose (FDG) PET-CT for staging of NSCLC. CTTA comprised image filtration to extract fine, medium and coarse features with quantification of the distribution of pixel values (uniformity) within the filtered images. Receiver operating characteristics identified thresholds for PET and CTTA parameters that were related to patient survival using Kaplan-Meier analysis.
The median (range) survival was 29.5 (1–38) months. 24, 10, 14 and 6 patients had tumour stages I, II, III and IV respectively. PET stage and tumour heterogeneity assessed by CTTA were significant independent predictors of survival (PET stage: Odds ratio 3.85, 95% confidence limits 0.9–8.09, P = 0.002; CTTA: Odds ratio 56.4, 95% confidence limits 4.79–666, p = 0.001). SUV was not a significantly associated with survival.
Assessment of tumour heterogeneity by CTTA of non-contrast enhanced images has the potential for to provide a novel, independent predictor of survival for patients with NSCLC.
• Computed tomography is a routine staging procedure in non-small cell lung cancer
• CT texture analysis (CTTA) can quantify heterogeneity within these lung tumours
• CTTA seems to offer a novel independent predictor of survival for NSCLC
• CTTA could contribute to disease risk-stratification for patients with NSCLC
KeywordsLung cancer Survival Computed tomography Positron emission tomography Texture analysis
B.G. and K.M. have a commercial interest in the tumour structural analysis software described in MS.
The authors acknowledge the statistical input given by Dr. Matthew Hankins, Senior Lecturer in Clinical Research Methodology, Division of Primary Care & Public Health & Institute of Postgraduate Medicine, Brighton & Sussex Medical School, Falmer BN1 9PH.
- 1.World Health Organization. The global burden of disease: 2004 update (2008); Available at http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part2.pdf. Accessed February 7, 2011
- 2.American Cancer Society (2010) Cancer Facts and Figures 2010. American Cancer Society. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf. Accessed February 7, 2011
- 5.Rami-Porta R, Crowley JJ, Goldstraw P (2009) The revised TNM staging system for lung cancer. Annals of Thoracic Cardiovascular Surgery Feb 15:4–9Google Scholar
- 10.Alongi F, Ragusa P, Montemaggi P et al (2006) Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumouri 92:327–33Google Scholar
- 11.Berghmans T, Dusart M, Paesmans M et al (2008) Primary tumour standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC). A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC lung cancer staging project. J Thorac Oncol 3:6–12PubMedCrossRefGoogle Scholar
- 29.Ganeshan B, Mandeville H, Burke M, et al (2010) CT of Non-Small Cell Lung Cancer (NSCLC): Histopathological Correlates for Texture Parameters. In Radiological Society of North America (RSNA), Chicago, USAGoogle Scholar